Photocure ASA (0IMT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Alright. Well, great. Welcome everyone to Photocure ASA's first quarter twenty six results. I'm Dan Schneider, president and CEO. Today, with me will be Dick Peters. He's controller for Photocure. Eric Dahl, our CFO, is out ill today, and also Priyam Shah, vice president of relations. Just a reminder, the usual disclaimers are in effect for today's presentation. So Photocure's corporate strategy is built on three priorities guiding execution and capital allocation. The first pillar is strengthening the core HEX VIX and SYSVUE business, driving disciplined revenue and EBITDA growth while expanding operating leverage. US, we wanna scale the blue light cystoscopy mobile VorTeq along with the tower installations and upgrades with the goal of increasing BLC inactive and upgraded accounts, so increasing that throughput. And in The EU, we wanna increase penetration in the key EU markets through BLC expansion, image upgrades, and broader distribution reach, and we'll talk more about these today. We also wanna be a lead in the standard, establishing BLC as a primary precision diagnostic across detection, surveillance, and the monitoring of non muscle invasive bladder cancer. We also support next generation high def BLC adoption via the OEM upgrades and new OEM entrants. As we mentioned in today's presentation, Stryker has now entered the blue light cystoscopy market in Europe, and that is extremely exciting, if you know anything about the Stryker organization. And then partner with Richard Wolff to grow FlexVLC in Europe while advancing our co development of the four k global system for a proprietary launch in 2027 on a global scale. And the third pillar, expanding our platform. We wanna build a broader uro oncology and precision diagnostic platform, be it biomarkers, artific...